Spectranetics Corp  

(Public, NASDAQ:SPNC)   Watch this stock  
Find more results for Kimberly McIntosh
-0.41 (-1.18%)
Apr 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.98 - 34.65
52 week 20.07 - 37.04
Open 34.65
Vol / Avg. 395,381.00/387,165.00
Mkt cap 1.47B
P/E     -
Div/yield     -
EPS -0.98
Shares 42.17M
Beta 1.08
Inst. own 107%
Apr 23, 2015
Q1 2015 Spectranetics Corp Earnings Release Add to calendar
Feb 19, 2015
Q4 2014 Spectranetics Corp Earnings Call - Webcast
Feb 19, 2015
Q4 2014 Spectranetics Corp Earnings Release
Jan 14, 2015
Spectranetics Corp at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -23.40% -19.96%
Operating margin -21.87% -18.03%
EBITD margin - 2.49%
Return on average assets -12.62% -11.96%
Return on average equity -35.28% -23.23%
Employees 753 -
CDP Score - -


9965 Federal Dr
United States - Map
+1-719-6338333 (Phone)
+1-877-4472022 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company�s products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. The Company offers excimer laser system known as the CVX-300. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of blockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries (coronary atherectomy); support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); and thrombectomy catheters for the removal of thrombus (thrombus management). The Company�s Lead Management business unit includes excimer laser sheaths, non-laser sheaths and cardiac lead management accessories.

Officers and directors

R. John Fletcher Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Scott William Drake President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Guy A. Childs Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shahriar Matin Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
Paul Gardon Senior Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Kimberly McIntosh Bridges Senior Vice President - Sales and Marketing of Vascular Intervention
Age: 40
Bio & Compensation  - Reuters
Donna Ford-Serbu Senior Vice President - Sales and Marketing of Lead Management
Age: 45
Bio & Compensation  - Reuters
Robert Michael Fuchs Senior Vice President, Global Head - Human Resources
Age: 47
Bio & Compensation  - Reuters
Austin B. Byrd Chief Compliance Officer, Vice President
Age: 48
Bio & Compensation  - Reuters
Wade A. Bowe Vice President - Research & Development
Age: 43
Bio & Compensation  - Reuters